Navigation Links
Synvista Therapeutics' Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
Date:10/25/2007

tor for AGEs) signaling in an in vivo model of diabetes. He used two drugs aminoguanidine, a well characterized inhibitor of AGE formation, and alagebrium, a novel compound that acts as an AGE-crosslink breaker. The study showed that diabetes resulted in an accumulation of serum AGEs and that there was a 50% reduction in myenteric nNOS expression which was reversible by either aminoguanidine or alagebrium. This is the first reported evidence for the potential importance of AGE signaling in the pathogenesis of enteric neuropathy. In this study, late administration of alagebrium reduced serum AGEs to control levels and also restored nNOS levels. Further studies will be needed to understand the mode of action of alagebrium, however, the results of the study suggest that countering the AGE-RAGE signaling pathway may be a major target for diabetes related gastrointestinal complications, particularly those that arise from reduction of nNOS expression.

"I am quite enthused by the observation that alagebrium may preserve nNOS activity, which would allow it to advance as a leading candidate for clinical development in the fight against this challenging disease," said Dr. Pasricha.

Patients with diabetes commonly experience gastric and intestinal dysfunction, however, the mechanism of how this happens is not well understood. The term diabetic enteropathy is often used to explain the disturbance in bowel function such as chronic diarrhea which occurs in 15% or more diabetics. A role for decreased nNOS expression has been suggested as a possible cause for the diarrhea however how diabetes causes such changes in nNOS expression levels is unknown. Dr. Raj Kumar will continue to work on how glycation of nNOS affects its structure and function.

"Dr. Pasricha's ground breaking work may be the first step in providing treatment for gastrointestinal disorders resulting from diabetes," said Noah Berkowitz, M.D., Ph. D. President and Chief Executive Officer of Synvista.
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015  Array BioPharma Inc. ... Chief Executive Officer, Ron Squarer , will ... in Boston.  The public is welcome to participate ... Array BioPharma website.Event: Wells Fargo Securities Healthcare ConferencePresenter: ... 10, 2015Time:  , 10:20 a.m. Eastern Time Webcast: ...
(Date:9/2/2015)... , Sept. 2, 2015 ... revenue base with highly profitable specialty products ... Near-term growth potential with 11 product applications pending ... IV certifications  , Provides medium and longer ... development, including eight controlled substances , Adds ...
(Date:9/2/2015)... Sept. 2, 2015 Research and Markets ( http://www.researchandmarkets.com/research/l8z67c/pharmaceutical ... Affairs in China (Basel, Switzerland - November 26-27, 2015)" ... provide a detailed overview of the key areas of pharmaceutical ... Hong Kong , Macau and ... - All important aspects of gaining and maintaining a ...
Breaking Medicine Technology:Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 2Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 3Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 4Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 5Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 6Pharmaceutical Regulatory Affairs in China Seminar: Basel, Switzerland - November 26-27, 2015 2
... today announced the,publication of the results from a ... cruciate ligament (ACL) reconstruction,surgery. OMS103HP is an investigational ... and is designed to improve postoperative,knee function and ... return to work. The article titled "Novel Drug ...
... PHILADELPHIA, Aug. 25 Scientists have,discovered gene mutations ... the childhood cancer neuroblastoma. In addition, the researchers found,that ... forms of,non-inherited neuroblastoma, the more common form of the ... first genetic tests to families,affected by the inherited form ...
Cached Medicine Technology:Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery 2Gene That Causes Childhood Cancer Neuroblastoma Is Found 2Gene That Causes Childhood Cancer Neuroblastoma Is Found 3Gene That Causes Childhood Cancer Neuroblastoma Is Found 4
(Date:9/3/2015)... ... September 03, 2015 , ... The new ... Report of Provo, Utah. The Clinicians Report is a leading information source to ... located throughout the U.S. Whiter Image's In-Office whitening kits were favorably validated for ...
(Date:9/3/2015)... ... ... Local filmmakers and now co-hosts of the up and coming podcast Path11 ... had great success in launching their Path11 Podcast with 23 episodes released since April ... is the well known Spiritual Catalyst and Linda Howe, leader in the field of ...
(Date:9/3/2015)... ... September 03, 2015 , ... The partnership ... customer and technical support services to promote LodonalTM in Nigeria. The distribution will ... the efficacy and safety of the product. , Managing Director, Fidson Healthcare Plc, ...
(Date:9/2/2015)... ... ... One can hardly argue against the fact that more and more people are using ... are being used as GPS, to make purchases, and yes, even to find a ... can now join the prestigious social ranks of e-dating. , Recently, Mr. Josh ...
(Date:9/2/2015)... Poulsbo, WA (PRWEB) , ... September 02, 2015 , ... ... store, open September 2015. “It was a simple decision, really,” says Chris. “We have ... shop here. They know the brands that work best for them—so we’ve given them ...
Breaking Medicine News(10 mins):Health News:Whiter Image Products Get Positive Rating From The Clinicians Report 2Health News:Path 11 Podcast Now Features over 20 Metaphysical Discussions on iTunes and Growing 2Health News:Path 11 Podcast Now Features over 20 Metaphysical Discussions on iTunes and Growing 3Health News:Fidson Partners US Firms on New Product Marketing 2Health News:Fidson Partners US Firms on New Product Marketing 3Health News:Fidson Partners US Firms on New Product Marketing 4Health News:Herpes-datingsites.com Recently Added Reviews of 5 STD Dating Apps for STD Positive Singles 2Health News:Harrison's Comfort Footwear Announces Expansion with New CHarrison Online Store 2
... Diabetes Will Meet Nick Jonas in Los Angeles and,Become ... N.Y., Oct. 30 To kick off Diabetes Awareness,Month, ... have,won the opportunity to meet teen pop sensation Nick ... In Nick,s Shoes" (W.I.N.S.),sweepstakes. These Grand Prize winners will ...
... last Sunday in March increases the risk of myocardial infarction ... in the autumn reduces the risk, albeit to a lesser ... the prestigious New England Journal of Medicine . , ... myocardial infarction in Sweden has changed with the summer and ...
... off American,Diabetes Month this November, the American Diabetes ... along with Eli,Lilly and Company,s national educational initiative, ... Update, an educational program for people affected by ... November 1, at the Greater,Grace Temple, 23500 W. ...
... Resource for Sharing Product, Educational Expertise,with ASCs, ... Braun Medical Inc. (B.,Braun) has launched a ... educational and editorial information for ambulatory surgical ... The new online resource, http://www.asc.bbraunusa.com, ...
... First Company to Reach Pivotal Study for Spine Nucleus ... Technology,Inc. announced today, the U.S. Food and Drug Administration ... the NuBac(R) Nucleus,Replacement Device for the spine., Pioneer,s ... MD, MBA,says, "This is a huge milestone and accomplishment ...
... Therapeutics,Inc. (OTC Bulletin Board: ARNI.OB), a clinical-stage biopharmaceutical,company ... William F. Hamilton, Ph.D. to its Board of ... Hamilton has over 40 years experience as a,professor ... the areas of,technology strategy and planning, entrepreneurship and ...
Cached Medicine News:Health News:Bayer Diabetes Care Names 'Walk In Nick's Shoes' (W.I.N.S.) Sweepstakes Grand Prize Winners 2Health News:Bayer Diabetes Care Names 'Walk In Nick's Shoes' (W.I.N.S.) Sweepstakes Grand Prize Winners 3Health News:Clock-shifts affect risk of heart attack 2Health News:American Diabetes Association and Eli Lilly and Company Unite to Educate and Empower African-Americans with Diabetes 2Health News:American Diabetes Association and Eli Lilly and Company Unite to Educate and Empower African-Americans with Diabetes 3Health News:B. Braun Medical Inc. Launches Ambulatory Surgical Center Website 2Health News:Pioneer(R) Surgical Technology's NuBac(R) Nucleus Replacement Device Wins FDA Approval for IDE Pivotal Study 2Health News:Pioneer(R) Surgical Technology's NuBac(R) Nucleus Replacement Device Wins FDA Approval for IDE Pivotal Study 3Health News:Arno Therapeutics Appoints William F. Hamilton to Board of Directors 2Health News:Arno Therapeutics Appoints William F. Hamilton to Board of Directors 3
The Perfecta PDA components provide the design and material choice imperative in today's cost conscious medical climate....
Cementless hip stem revisions offering optimal version setting for each patient. Compatible with modular link ceramic or cobalt chromium femoral heads with up to 4 neck lengths, or the link saddle de...
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
Medicine Products: